<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336452">
  <stage>Registered</stage>
  <submitdate>26/01/2011</submitdate>
  <approvaldate>4/02/2011</approvaldate>
  <actrnumber>ACTRN12611000127909</actrnumber>
  <trial_identification>
    <studytitle>Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight</studytitle>
    <scientifictitle>A randomized, double-blind, placebo-controlled trial cyproheptadine versus a placebo for appetite stimulation in patients with cystic fibrosis</scientifictitle>
    <utrn>U1111-1119-2162</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <healthcondition>Malnutrition</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention group will receive cyproheptadine for a period of 12 weeks and the control group will receive placebo for the same period.
In the first week 2mg three times a day
In the next weeks 4mg three times daily

Mode of administration: Syrup with a concentration of 1 ml
 
The patient gets two bottles:
 In the first week, in the intervention group
 taking the syrup, where each ml is the concentration of 2 mg of cyproheptadine.
 In the rest  week, the intervention group takes the syrup has a concentration of 4 mg per ml.</interventions>
    <comparator>The control group will syrups with taste and appearance similar to cyproheptadine, but will be placebo.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Weight gain in patients with cystic fibrosis</outcome>
      <timepoint>The result will be evaluated by the measurement of weight, height and arm circumference of the skinfolds. Results are expressed as z score and percentile</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the food consumption and nutritional status of patients with cystic fibrosis before and after the intervention, in the intervention and control groups</outcome>
      <timepoint>Food consumption is measured by food frequency questionnaire</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlate food intake pulmonary function and with nutritional status</outcome>
      <timepoint>Will compare the spirometry performed on the first day of treatment and after the twelve weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* patients aged between 5 and 18 years;
* qualified to spirometry;
* weight / age &lt;100%.</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with intolerance to antihistamines, patients using sedative or narcotic drugs, patients that have taken appetite stimulants or steroids for 30 days before the study, inability to do spirometry.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The pharmaceutical patients randomized in blocks by Pepi software, to receive placebo or cyproheptadine The researcher who delivered the envelopes to the patients, had no knowledge of its contents because the allocation was concealed in sealed opaque envelopes</concealment>
    <sequence>Block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>19/05/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Regina Nejedlo</primarysponsorname>
    <primarysponsoraddress>Rua Mostardeiro, 455
Loja 07
Independencia, Porto Alegre / RS
Cep: 90430-001</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Pontificia Universidade Catolica do Rio Grande do Sul</fundingname>
      <fundingaddress>Instituto de Pesquisas Biomedicas - IPB
Hospital Sao Lucas
Av Ipiranga, 6690 - 2 andar
Caixa Postal 1429
Porto Alegre - RS - Brasil
CEP 90610-000</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Pontificia Universidade Catolica do Rio Grande do Sul</sponsorname>
      <sponsoraddress>Instituto de Pesquisas Biomedicas - IPB
Hospital Sao Lucas
Av Ipiranga, 6690 - 2 andar
Caixa Postal 1429
Porto Alegre - RS - Brasil
CEP 90610-000</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study was to determine whether the administration of Cyproheptadine (CH) was able to induces weight gain, improving food consumption and pulmonary function in patients with cystic fibrosis (CF).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica do Hospital Sao Lucas da PUCRS</ethicname>
      <ethicaddress>Av. Ipiranga 6690
Predio 60 - Sala 314
Porto Alegre - RS - Brasil
CEP 90610-900</ethicaddress>
      <ethicapprovaldate>16/04/2010</ethicapprovaldate>
      <hrec>10\4985</hrec>
      <ethicsubmitdate>1/01/2010</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comite de Etica da Irmandade Santa Casa de Misericordia</ethicname>
      <ethicaddress>Rua Prof. Annes Dias, 295
Cep: 90020-090
Porto Alegre -RS - Brasil</ethicaddress>
      <ethicapprovaldate>10/08/2010</ethicapprovaldate>
      <hrec>311/010</hrec>
      <ethicsubmitdate>15/06/2010</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Renato Tetelbom Stein</name>
      <address>Instituto de Pesquisas Biomedicas - IPB
Hospital Sao Lucas
Av Ipiranga, 6690 - 2 andar
Caixa Postal 1429
Porto Alegre - RS - Brasil
Cep: 90610-000</address>
      <phone>+55 (51) 9972.6224</phone>
      <fax />
      <email>rstein@pucrs.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Larissa da Rosa Feix</name>
      <address>Faculdade de Medicina da PUCRS
Instituto de Pesquisas Biomedicas - IPB
Hospital Sao Lucas
Av Ipiranga, 6690 - 2 andar
Caixa Postal 1429
Porto Alegre - RS - Brasil
Cep: 90610-000</address>
      <phone>+55 (51) 9192.8811</phone>
      <fax />
      <email>larissafeix@hotmail.com</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Matias Epifanio</name>
      <address>Instituto de Pesquisas Biomedicas - IPB Hospital Sao Lucas Av Ipiranga, 6690 - 2 andar Caixa Postal 1429 - Porto Alegre - RS - Brasil Cep:90610-000</address>
      <phone>+55 (51) 99996248</phone>
      <fax />
      <email>mepifanio@hotmail.com</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>